ArticleCell reports2026
Synergistic cooperation between progranulin and Jak2/Stat3 signaling determines definitive myeloid cell fate.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Perturbations in cell fate disrupt tissue homeostasis and drive diseases such as cancer. The JAK/STAT pathway is central to hematopoietic malignancies, yet its regulators in cell fate decisions remain poorly defined. Here, we identify progranulin (GRN) as a critical determinant of myeloid fate through the regulation of JAK2/STAT3 signaling. Using inducible stat3 and grna zebrafish models, knockout approaches, FACS, transcriptomics, and CUT&RUN, we show that Stat3 induces grna, which in turn amplifies stat3 expression, reinforcing myeloid over erythroid commitment. Lineage tracing and live imaging reveal that this Grna/Stat3 feedback operates during definitive, but not primitive, myelopoiesis. Functionally, definitive myeloid cells drive tissue repair, whereas primitive counterparts are less effective. Myeloid differentiation in a human leukemia line required GRN co-stimulation of JAK2/STAT3, highlighting its conserved role in fate determination. These findings uncover a regulatory axis controlling hematopoietic commitment and identify GRN as a potential therapeutic target in diseases with aberrant JAK2/STAT3 activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.